Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of EuRSV in Healthy Adults
NCT06216093Phase 1Active, not recruiting
- Sponsor
- EuBiologics
- Start
- May 2024
- Primary completion
- Jul 2025
- Modality
- Targeted Liposomes, Recombinant Protein Vaccines, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EuRSV in respiratory syncytial virus infection (RSV) (3 arms), sponsored by EuBiologics. Primary endpoints: Occurrence of solicited adverse events at 7 days, Occurrence of immediate adverse events at 30 minutes and 2 more. Started May 2024; status: active, not recruiting.
02
Drugs
EuRSV
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06216093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06216093.